Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

ICOS Promotes the Function of CD4+Effector T Cells during Anti-OX40–Mediated Tumor Rejection

(2016) Todd C. Metzger et al.   CANCER RESEARCH

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

(2016) Karishma Rajani et al.   MOLECULAR THERAPY

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy

(2015) J. J. Rojas et al.   CLINICAL CANCER RESEARCH

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune checkpoint modulation: Rational design of combination strategies

(2015) Dmitriy Zamarin et al.   PHARMACOLOGY & THERAPEUTICS

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

(2014) Peter T. Sage et al.   IMMUNITY

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells

(2014) Y. Burmeister et al.   JOURNAL OF IMMUNOLOGY

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer

(2014) Dmitriy Zamarin et al.   Molecular Therapy-Oncolytics

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

B7-H2 Is a Costimulatory Ligand for CD28 in Human

(2011) Sheng Yao et al.   IMMUNITY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells

(2010) C. M. Paulos et al.   Science Translational Medicine

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists

(2009) K. S. Peggs et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus

(2009) Feorillo Galivo et al.   HUMAN GENE THERAPY

The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency

(2009) Patrick F. K. Yong et al.   IMMUNOLOGICAL REVIEWS

Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

(2009) Tsvetelina Pentcheva-Hoang et al.   IMMUNOLOGICAL REVIEWS

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

(2008) Karl S. Peggs et al.   IMMUNOLOGICAL REVIEWS

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells

(2008) Aurelie T Bauquet et al.   NATURE IMMUNOLOGY

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA